Latest news with #MotorNeuron
Business Upturn
17-07-2025
- Business
- Business Upturn
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032
New York, USA, July 17, 2025 (GLOBE NEWSWIRE) — Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight The motor neuron disease treatment market is witnessing substantial growth, primarily fueled by the rising incidence of conditions like Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Greater awareness around early and precise diagnosis is also contributing to this upward trend. Additionally, the market is transforming with a growing preference for biologic therapies that provide more targeted and effective treatment. Coupled with robust investment and ongoing advancements in research and development, these factors are creating a highly supportive landscape for market expansion. DelveInsight's Motor Neuron Disease Treatment Market Insights report provides the current and forecast market analysis, individual leading motor neuron disease treatment companies' market shares, challenges, motor neuron disease treatment market drivers, barriers, trends, and key market motor neuron disease treatment companies in the market. Key Takeaways from the Motor Neuron Disease Treatment Market Report As per DelveInsight estimates, North America is anticipated to dominate the global motor neuron disease treatment market during the forecast period. In the drug class segment of the motor neuron disease treatment market, the survival motor neuron (SMN) agonist category accounted for the largest market share in 2024. Notable motor neuron disease treatment companies such as Biogen, Mitsubishi Chemical Group Corporation, F. Hoffmann-La Roche Ltd., Otsuka Holdings Co., Ltd., Sanofi, Ionis Pharmaceuticals, Inc., Novartis AG, EDW Pharma, Inc., PTC Therapeutics, Inc., Chugai Pharmaceutical Co., Ltd., AMYLYX Pharmaceuticals, and several others are currently operating in the motor neuron disease treatment market. and several others are currently operating in the motor neuron disease treatment market. In June 2025, Roche announced that the European Commission (EC) had approved a label extension for EVRYSDI (risdiplam), allowing the inclusion of a new room-temperature stable tablet formulation for individuals living with Spinal Muscular Atrophy (SMA). This advancement enhances treatment convenience and accessibility, particularly for patients who require flexible, at-home administration. announced that the European Commission (EC) had approved a label extension for EVRYSDI (risdiplam), allowing the inclusion of a new room-temperature stable tablet formulation for individuals living with Spinal Muscular Atrophy (SMA). This advancement enhances treatment convenience and accessibility, particularly for patients who require flexible, at-home administration. In January 2025, Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted the company's supplemental New Drug Application (sNDA), and the European Medicines Agency (EMA) had validated its application for a higher dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). This development marks an important step toward potentially enhancing the therapeutic benefits of nusinersen by optimizing dosing for improved clinical outcomes in SMA patients. To read more about the latest highlights related to the motor neuron disease treatment market, get a snapshot of the key highlights entailed in the Global Motor Neuron Disease Treatment Market Report Motor Neuron Disease Treatment Overview Motor neuron disease (MND), including its most common form, amyotrophic lateral sclerosis (ALS), currently has no cure, but treatment focuses on managing symptoms, slowing disease progression, and improving quality of life. Pharmacological options include riluzole, which modestly extends survival by reducing damage to motor neurons, and edaravone, which may slow functional decline in some patients. Supportive treatments such as muscle relaxants, antispasmodics, and antidepressants help manage complications like spasticity, cramps, and emotional lability. Nutritional support, often via feeding tubes in advanced stages, and respiratory interventions like non-invasive ventilation (NIV) are crucial in maintaining function and comfort. A multidisciplinary approach is central to MND care. Patients typically benefit from coordinated support by neurologists, physiotherapists, occupational therapists, speech and language therapists, and palliative care specialists. Physiotherapy helps maintain mobility and prevent contractures, while speech therapy supports communication and safe swallowing. Assistive devices and home modifications can enhance independence. Psychosocial support for both patients and caregivers is essential, given the emotional burden of a progressive, terminal illness. Emerging areas of research include gene therapy, stem cell treatment, and antisense oligonucleotides, offering hope for future disease-modifying interventions. Motor Neuron Disease Treatment Market Insights North America dominated the global motor neuron disease treatment market in 2024, owing to a blend of structural strengths and strategic advantages. This regional leadership is largely due to the growing incidence of motor neuron disorders like ALS and SMA, which are placing increasing pressure on healthcare systems to deliver effective therapeutic options. The presence of a strong pharmaceutical ecosystem, comprising top biotech and pharma firms, continues to fuel advancements through research, clinical trials, and commercialization of cutting-edge treatments. Regulatory agencies, particularly the FDA, play a key role by providing accelerated approval pathways for rare disease therapies, helping speed up market entry for innovative MND treatments. Together, the rising disease burden, vibrant R&D activity, and favorable regulatory landscape are positioning North America at the forefront of the global MND treatment market. One of the main growth drivers in the region is the increasing occurrence of SMA, which has significantly boosted demand for disease-modifying therapies. As SMA often appears in infancy or early childhood, there is a pressing need for early genetic screening and novel treatments like SMN-targeted gene therapies. This urgency has led to substantial investment in research and therapeutic innovation. The region's growth trajectory is further supported by a progressive regulatory framework. The FDA has played a crucial role in advancing the MND treatment field by granting fast-track and breakthrough therapy designations to promising drugs. A prominent example is ZOLGENSMA, a gene therapy for SMA, which received accelerated approval, marking a major step forward in gene-based interventions. Moreover, ongoing efforts by U.S.-based pharmaceutical companies are reinforcing this momentum. For instance, in April 2023, Biogen Inc. secured FDA accelerated approval for QALSODY (tofersen), an intrathecal treatment for ALS patients with SOD1 mutations. This approval was based on the drug's ability to lower neurofilament light chain (NfL) levels, a key biomarker of neuronal injury, positioning QALSODY as a new precision medicine option in the U.S. Overall, the interplay of rising disease prevalence, continuous innovation, strong regulatory backing, and strategic moves by industry leaders is expected to drive sustained growth in the North American MND treatment market from 2025 through 2032. To know more about why North America is leading the market growth in the motor neuron disease treatment market, get a snapshot of the Motor Neuron Disease Treatment Market Outlook Motor Neuron Disease Treatment Market Dynamics The motor neuron disease treatment market is undergoing a period of significant transformation, driven primarily by the increasing incidence of motor neuron disorders such as Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, and Spinal Muscular Atrophy. With aging populations and improved diagnostic capabilities, the global prevalence of these conditions is steadily rising. This growing patient population is pushing healthcare systems and pharmaceutical companies to prioritize research and development of effective therapies, leading to the emergence of novel treatment approaches and expanding market opportunities. One of the most notable market dynamics is the shift from symptomatic management toward disease-modifying and targeted therapies. Advances in genetic research and neurobiology have enabled the development of more precise treatments, such as antisense oligonucleotides and gene therapies. These innovations not only offer the potential to slow or halt disease progression but also significantly improve the quality of life for patients. However, their high costs and logistical challenges in delivery remain barriers to widespread adoption, particularly in lower-income regions. Another key trend is the growing role of collaborations and partnerships among biotech firms, academic institutions, and large pharmaceutical companies. These alliances are facilitating faster clinical development and regulatory approvals, especially through the use of orphan drug designations and accelerated pathways provided by agencies like the FDA and EMA. Additionally, patient advocacy groups have become increasingly influential in driving funding, awareness, and policy change, further boosting the momentum behind MND research and treatment initiatives. Despite these positive trends, the MND treatment landscape faces several ongoing challenges. Many therapies still offer only modest efficacy, and drug development is complicated by the heterogeneity of disease presentation and progression among patients. Furthermore, there remains a critical unmet need for effective treatments for ALS, the most common and aggressive form of MND, where options like riluzole and edaravone provide only limited benefits. As such, the market continues to be characterized by high unmet need and significant opportunity for breakthrough innovations. In conclusion, the motor neuron disease treatment market is poised for long-term growth, supported by scientific advancements, increased investment, and rising global awareness. However, realizing the full potential of this market will depend on overcoming barriers related to cost, access, and therapeutic efficacy. Stakeholders will need to continue fostering innovation, improving early diagnosis, and ensuring equitable access to emerging therapies to truly transform the treatment landscape for motor neuron diseases. Get a sneak peek at the motor neuron disease treatment market dynamics @ Motor Neuron Disease Treatment Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Motor Neuron Disease Treatment Market CAGR ~6% Key Motor Neuron Disease Treatment Companies Biogen, Mitsubishi Chemical Group Corporation, F. Hoffmann-La Roche Ltd., Otsuka Holdings Co., Ltd., Sanofi, Ionis Pharmaceuticals, Inc., Novartis AG, EDW Pharma, Inc., PTC Therapeutics, Inc., Chugai Pharmaceutical Co., Ltd., AMYLYX Pharmaceuticals, among others Motor Neuron Disease Treatment Market Assessment Motor Neuron Disease Treatment Market Segmentation Motor Neuron Disease Treatment Market Segmentation By Drug Class: NMDA (N-methyl-D-aspartate) Receptor Antagonist, SOD1 Gene Mutation Agonist, Alpha-2 Adrenergic Agonist, Survival Motor Neuron (SMN) Agonist, and Others Motor Neuron Disease Treatment Market Segmentation By Route of Administration: Oral and Parenteral Motor Neuron Disease Treatment Market Segmentation By Indication: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Others Motor Neuron Disease Treatment Market Segmentation By Distribution Channel: Hospitals and Retail Pharmacies, and Online Pharmacies Motor Neuron Disease Treatment Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the motor neuron disease treatment market are set to emerge as the trendsetter explore @ Motor Neuron Disease Treatment Agent Table of Contents 1 Motor Neuron Disease Treatment Market Report Introduction 2 Motor Neuron Disease Treatment Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Motor Neuron Disease Treatment Market Key Factors Analysis 6 Motor Neuron Disease Treatment Market Porter's Five Forces Analysis 7 Motor Neuron Disease Treatment Market Layout 8 Motor Neuron Disease Treatment Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the motor neuron disease treatment market by 2032? Click to get a snapshot of the Motor Neuron Disease Treatment Market Analysis Related Reports Amyotrophic Lateral Sclerosis Market Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALS companies, including AB SCIENCE, ALECTOR, GSK, BRAINSTORM CELL THERAPEUTICS, IONIS PHARMACEUTICALS, MEDICINOVA, DENALI THERAPEUTICS, ABBVIE, CALICO LIFE SCIENCES, CLENE NANOMEDICINE BIOSCIENCES, SEELOS THERAPEUTICS, PRILENIA THERAPEUTICS, RAPA THERAPEUTICS, NEUROSENSE THERAPEUTICS, HELIXMITH, TRANSPOSON THERAPEUTICS, REVALESIO CORPORATION, ANNEXON BIOSCIENCES, CORCEPT THERAPEUTICS, AL-S PHARMA, SANOFI, DENALI THERAPEUTICS, ORPHAI THERAPEUTICS, among others. Amyotrophic Lateral Sclerosis Pipeline Amyotrophic Lateral Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ALS companies, including Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, among others. Spinal Muscular Atrophy Market Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SMA companies, including Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, among others. Spinal Muscular Atrophy Pipeline Spinal Muscular Atrophy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SMA companies, including Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Irish Independent
01-06-2025
- Health
- Irish Independent
‘It's an amazing atmosphere' – feel-good day in the capital as 28,000 take part in VHI Women's Mini Marathon
The first day of June showed early signs of a dreary day out for the 28,000 taking part in the annual run. There were spits of drizzle throughout the morning and an unseasonable breeze blew around the capital, but by early afternoon the sun was shining bright to bring a day more befitting the season. Moving through the city centre, it was clear the weather would be no deterrent regardless. Hours before the 12.30pm start-time, the streets were dotted with the purple t-shirts synonymous with an event now in its 43rd year. Among the competitive runners on the day, it was Grace Richardson of Kilkenny City Harriers who took first place with a time of 34:17. She was followed by Claire Fagan from Mullingar Harriers AC In third place was Jessica Craig of North Down AC on 34:55. The Visually Impaired category was won by Sinead Kane from the Le Chéile Athletic Club with a time of 44:26. More than €2 million has already been raised this year alone, bringing the total amount of money raised by the Mini Marathon up to more than €255 million since it was first held in 1982. Many taking part in the Mini Marathon do so for a good cause, including Castleknock woman Amy Kane, her sisters Kim and Erin Lynch and large group of other family and friends. The group were running in aid of the LauraLynn Children's Hospice, and all wore t-shirts with the LauraLynn logo and pictures of Ms Kane's baby daughter Grace, who sadly died just three months after she was born. 'My little girl Grace was under the care of LauraLynn,' Ms Kane said. 'She was unfortunately diagnosed with meningitis when she was 18 days old. She was under the care of LauraLynn and she passed away at three months old. ADVERTISEMENT Ms Kane said the care provided by LauraLynn wasn't just for Grace, but also for the entire family. 'Grace was a triplet, so her sisters Cara and Chloe were premature as well, they were born at 32 weeks. We had to stay in LauraLynn for three weeks before Grace passed away. Ms Kane described how the charity had cots for Cara and Chloe. Their brother James was only 18 months old at the time, so they had a toy corner for the toddler. 'It was just after Covid and they made it possible for all our family and friends to come in and meet Grace before she passed away. They're amazing, we're still very close to them and we'll continue to support them.' Blanchardstown neighbours Stephen McGovern and Charlie and Aileen Boyd, running separately for different causes, ran into each other on their way to the starting line. Decked out in a blonde wig and short shorts, Mr McGovern had already raised €500 for the Irish Motor Neuron Disease Association. He said for every €10 he raised, a strip of hair was waxed from his legs and sure enough, his legs were hairless. He was running in memory of his aunt Eilish, who died following a battle with the disease. 'My aunt passed away from Motor Neuron about 12 years ago and between myself and a few other family members, we've always raised money,' he said. 'It's a disease that has no cure at the moment, so helping families get the support that they need and getting the charity the funds that they deserve is the right thing to do.' Mr McGovern said he is conscious of the Mini Marathon being an event for women, but he felt running for a woman who can no longer run it herself anymore was appropriate. 'I've always believed the Women's Mini Marathon is a women's event, but men should do it if they're raising money for a women's charity or in place of a woman who can't run. "So, raising money in that direction is the right thing to do and since it's such an amazing atmosphere, supporting her since she's passed, it makes it more fun.' Further south, the Cork City Marathon and Half Marathon races were also held on Sunday, where Clare man Chris Jeuken of Derg AC took first place in the marathon, just three weeks after winning the Limerick half marathon. Mr Jeuken, who finished with a time of two hours, eighteen minutes and 55 seconds, was greeted at the finish line by his girlfriend Olivia Gurnett who herself ran the 10km race today. The leading woman in the Cork City Marathon was Evelyn Twomey with a time of two hours and 54 minutes. A total of more than 11,000 people took part across the marathon, half marathon and 10km in Cork including 550 international runners from 26 countries.
